Clinical Trials on Hypoparathyroidism in Hungary

Total 21 results

Amolyt Pharma

Completed

AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism

Chronic Hypoparathyroidism

Hungary, Netherlands
Shire

Completed

A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary (REPEAT)

Hypoparathyroidism

Hungary
Amolyt Pharma

Active, not recruiting

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism (CALYPSO)

Endocrine System Diseases | Parathyroid Diseases | Chronic Hypoparathyroidism

United States, United Kingdom, Spain, Italy, Netherlands, Denmark, Hungary, Portugal, Germany, France, Canada, Poland
Shire

Terminated

Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism

Hypoparathyroidism

United States, Hungary, Denmark, Canada
Chugai Pharmaceutical

Terminated

A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism

Hypoparathyroidism

United States, Canada, Hungary
Amgen

Recruiting

A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

Secondary Hyperparathyroidism

Spain, Belgium, Germany, Czechia, Poland, France, Greece, Hungary, Italy, United Kingdom, Lithuania, Portugal
Shire

Completed

Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism (PARALLAX)

Hypoparathyroidism

United States, Hungary, Canada, Denmark
Amgen

Completed

Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy

Hyperparathyroidism, Primary | Hypercalcemia

United States, Canada, Russian Federation, Hungary, Australia, Portugal, Poland
Amgen

Completed

Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis

Secondary Hyperparathyroidism, Chronic Kidney Disease

United States, Czechia, Germany, France, Hungary, Greece, Belgium, Italy, Poland, Russian Federation, Ukraine
Ascendis Pharma Bone Diseases A/S

Active, not recruiting

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism (PaTHway)

Endocrine System Diseases | Parathyroid Diseases | Hypoparathyroidism

United States, Canada, Norway, Denmark, Germany, Hungary, Italy
Shire

Completed

Use of NPSP558 in the Treatment of Hypoparathyroidism (REPLACE)

Hypoparathyroidism

United States, Denmark, Canada, Hungary, United Kingdom, Belgium, France, Italy
Amgen

Terminated

Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis

Chronic Kidney Disease, Secondary Hyperparathyroidism

United States, Belgium, Italy, Hungary, Czechia, France, Germany, Greece, Spain, Poland, Russian Federation, Ukraine, New Zealand, Slovakia, Lithuania, Portugal
AbbVie (prior sponsor, Abbott)
Planimeter Ltd

Completed

Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands

Kidney Failure, Chronic

Hungary
Amgen

Terminated

Pediatric Chronic Kidney Disease Safety and Efficacy

Hyperparathyroidism | Chronic Kidney Disease | Secondary Hyperparathyroidism | Hyperparathyroidism, Secondary | Kidney Disease

United States, Belgium, Hungary, Spain, Australia, Germany, Poland, Mexico, Russian Federation, Slovakia
Amgen

Completed

Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease (BONAFIDE)

Secondary Hyperparathyroidism

United States, Italy, Belgium, Switzerland, Hungary, Spain, Turkey, Poland, Portugal, United Kingdom, Czech Republic, Macedonia, The Former Yugoslav Republic of
Amgen

Completed

Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet

Chronic Kidney Disease | Secondary Hyperparathyroidism

United States, Italy, Belgium, Denmark, Switzerland, Canada, Turkey, Spain, Austria, Germany, Hungary, Greece, France, Poland, Russian Federation, Czechia, Latvia, Lithuania, New Zealand, Portugal, Sweden, Estonia
Amgen

Terminated

Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism

Chronic Kidney Disease | Hyperparathyroidism, Secondary

United States, Belgium, Italy, Hungary, Czechia, France, Germany, Poland, Netherlands, Russian Federation, New Zealand, Mexico, Slovakia
Amgen

Completed

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis

Hyperparathyroidism, Secondary

United States, Belgium, Italy, United Kingdom, Canada, Germany, Spain, Austria, Czechia, Hungary, France, Israel, Poland, Australia, Russian Federation
Amgen

Completed

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

Hyperparathyroidism, Secondary

United States, Belgium, Canada, France, Australia, Israel, Czechia, Hungary, Netherlands, Spain, Poland, Russian Federation, Italy, Sweden, Germany
Amgen

Completed

Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis

Hyperparathyroidism, Secondary

United States, Belgium, Italy, Switzerland, Canada, Turkey, Spain, Australia, Austria, Israel, Czechia, Hungary, Poland, France, Russian Federation, Germany, Denmark, Greece, Latvia, Lithuania, Netherlands, New Zealand, Portugal, Sweden
Amgen

Completed

Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

Hyperparathyroidism, Secondary

United States, Belgium, Italy, United Kingdom, Canada, Germany, Spain, Australia, Austria, Israel, Czechia, Hungary, Netherlands, Poland, France, Russian Federation, Sweden

Clinical Trials on Hypoparathyroidism in Hungary

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations